Fulcrum Therapeutics has told employees it is slashing roughly 85% of its workforce, effectively shrinking the Cambridge clinical-stage biotech to a skeleton crew as it winds down its lead sickle-cell program and launches a formal strategic review. The move follows regulatory feedback that, according to the company, wiped out any viable path forward for pociredir, Fulcrum's only late-stage asset, and has pushed the board to explore mergers, asset sales and other options to hang on to shareholder value.
According to the Boston Business Journal, staff were notified earlier this week that about 85% of roles would be eliminated, and Fulcrum has brought in Leerink Partners to help evaluate strategic alternatives. Managers delivered the bad news in small-group meetings and follow-up emails, the outlet reported.
Pociredir Pulled And Strategy Put Under The Microscope
In a June 1 press release, Fulcrum Therapeutics said it is discontinuing development of pociredir after FDA "end-of-phase" meeting minutes raised malignancy concerns tied to the PRC2 complex. "We have made the very difficult decision to discontinue development of pociredir," CEO Alex C. Sapir said, adding that the board has kicked off a comprehensive strategic review intended to "maximize stockholder value."
The company also disclosed that it held $333.3 million in cash, cash equivalents and marketable securities as of March 31, 2026, and that it is moving to cut operating expenses while that review plays out.
Regulatory Shockwaves And A Market Beatdown
The FDA stance did not emerge in a vacuum. Earlier this year, the global withdrawal of Tazverik (tazemetostat) raised class-wide safety questions for PRC2 inhibitors and fed directly into regulators' concerns. Reuters reporting, republished by Yahoo Finance, noted that Fulcrum's stock cratered more than 50% after the announcement and several brokerages cut their ratings, ramping up pressure on the company to move quickly through its strategic-review process.
Cambridge Feels The Fallout
Fulcrum's most recent SEC filing shows it had 55 full-time employees as of Feb. 17, 2026, according to the company's Form 10-K. An 85% reduction would leave roughly eight people on staff, turning what was a modest but active biotech shop into a bare-bones operation.
That kind of drawdown will ripple across Cambridge's dense web of lab vendors, landlords and nearby startups that rely on companies like Fulcrum for contract research and services. For now, the company has said it will stay quiet until the board settles on a path forward and formally signs off.
Lawyers Circle As Investors Weigh Options
The market plunge has not gone unnoticed by the plaintiffs' bar. PR Newswire reported that Levi & Korsinsky has opened an investigation into the company's officers and directors following the shutdown of the pociredir program. Other shareholder firms have issued similar notices as investors sift through the wreckage of the rapid stock decline and consider potential claims.
Fulcrum, for its part, says its focus now is on conserving capital and pursuing strategic alternatives. Until that process produces a concrete plan, the company is signaling that there will be few, if any, additional public updates.
